Delving into the Latest Updates on Thymopentin with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Thymopentin (USAN/INN)

+ [3]

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [1]

Active Indication

Hepatitis B, ChronicImmunologic Deficiency SyndromesRheumatoid Arthritis+ [1]

Inactive Indication

Sarcoidosis

Originator Organization-

Active Organization-

Inactive Organization

mondoBIOTECH Europe AG

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

Structure/Sequence

Molecular FormulaC30H49N9O9

InChIKeyPSWFFKRAVBDQEG-YGQNSOCVSA-N

CAS Registry69558-55-0

Sequence Code 10193

Source: *****

Developing bioactive delivery carriers with anti-inflammatory functions, long-term administration, and controlled release of multiple drugs is highly desirable owing to disease persistence over an extended period. In this study, a dynamically induced covalent assembly approach was used to fabricate thymopentin (TP5)-based carrier particles (TGCP) with biocompatibility and autofluorescence. The size and dispersibility of TGCP can be modulated by non-covalent interactions with hyaluronic acid (HA), endowing the system with excellent injectability and synergistic anti-inflammatory activity. Interestingly, the carrier can load a wide range of guest molecules with varying solubilities and achieve controlled gradient release in pathological and physiological environments. In addition, traditional Chinese-medicine-loaded TGCP/HA can effectively reduce the level of the inflammatory factor IL-6, indicating its potential anti-inflammatory properties. The TP5/HA-based material possesses excellent carrier properties and immunoreactivity, making it attractive for reducing inflammation at disease sites and long-term drug delivery in various chronic diseases.

01 Oct 2024·International Journal of Biological Macromolecules

Structural analysis of Salvia miltiorrhiza polysaccharide and its regulatory functions on T cells subsets in tumor-bearing mice combined with thymopentin

Article

Author: Ji, Haiyu ; Jia, Xiaoyu ; Long, Yan ; Yu, Juan ; Liu, Anjun ; Zheng, Guoqiang ; Dai, Keyao ; Fan, Yuting

Salvia miltiorrhiza ethanol-extracted polysaccharide (SMEP) and thymopentin (TP5) have been proved with strong immunomodulatory activity, and T cells subsets play pivotal roles in the inhibition of solid tumors growth. In the present study, the structure of SMEP was further identified via methylation and nuclear magnetic resonance spectra, and the immunomodulatory activity in combination with TP5 was investigated via evaluating T cell subsets spatial distributions in tumor-bearing mice, finally the cellular status of solid tumor cells was analyzed. The results revealed that SMEP was a neutral heteropolysaccharide using (1 → 4)-α-D-Glcp and (2 → 1)-β-D-Fruf as the main chain, along with branched chains of (1 → 6)-α-D-Galp. The SMEP+TP5 treatments could effectively promote the differentiation and improve the specific recognition capacity of CD4⁺ T cells in tumor-bearing mice, thereby activate tumor-infiltrating CD8⁺ T cells to exert cytotoxic effects, finally promoting the tumor cells apoptosis via blocking cell cycle at G0/G1 phase, which might be relevant with suppression of Wnt/β-catenin signaling pathway. These findings highlighted the potential of SMEP as an immunoadjuvant for patients bearing immune-deficiency related diseases, and provided data support for the functional researches of T cell subsets in tumor immunity.

01 Jan 2024·International Immunopharmacology

Thymopentin plays a key role in restoring the function of macrophages to alleviate the sepsis process

Article

Author: Chen, Yizhu ; Chen, Dechang ; Zhou, Chenghua ; Wen, Zhenliang ; Chen, Limin ; Liu, Jiao ; Li, Hui ; Huang, Sisi ; Zhang, Lidi ; Liu, Yongan ; Pan, Xiaojun ; Shen, Xuan ; Shang, Weifeng ; Zhang, Sheng

Immune dysfunction is one of the leading causes of death of sepsis. How to regulate host immune functions to improve prognoses of septic patients has always been a clinical focus. Here we elaborate on the efficacy and potential mechanism of a classical drug, thymopentin (TP5). TP5 could decrease peritoneal bacterial load, and reduce inflammatory cytokine levels both in the peritoneal lavage fluid (PLF) and serum, alleviate pathological injuries in tissue and organ, coaxed by cecal ligation and perforation (CLP) in mice, ultimately improve the prognosis of septic mice. Regarding the mechanism, using RNA-seq and flow cytometry, we found that TP5 induced peptidoglycan recognition protein 1 (PGLYRP1) expression, increased phagocytosis and restored TNF-α expression of small peritoneal macrophage (SPM) in the septic mice. This may be increased SPM's ability to clear peritoneal bacteria, thereby attenuates the inflammatory response both in the peritoneal cavity and the serum. It was shown that TP5 plays a key role in restoring the function of peritoneal macrophages to alleviate the sepsis process. We reckon that this is closely relevant to SPM phagocytosis, which might involve increased PGLYRP1 expression and restored TNF-α secretion.

100 Deals associated with Thymopentin

Login to view more data